SAN FRANCISCO, May 13 Medivation, Inc.(Nasdaq: MDVN) today announced that David Hung, M.D., president and chiefexecutive officer, will present at the following conferences.
Dr. Hung will provide an overview of Medivation and its clinicaldevelopment programs for Dimebon(TM) for Alzheimer's and Huntington's diseasesand MDV3100 for prostate cancer.
A live audio webcast of each presentation will be available on the "Eventsand Presentations" page of the "Investor Relations" section of the Company'swebsite at http://www.medivation.com. A replay also will be available for 30days following the live presentation.
Medivation, Inc. is a biopharmaceutical company focused on the rapiddevelopment and commercialization of innovative, life-changing therapeuticsthat effectively treat serious diseases with critical unmet medical needs,including diseases of the central nervous system and certain types of cancer.We aim to revolutionize treatment for deadly diseases that are not adequatelyaddressed by currently available medicines in order to bring relief andrenewed hope to seriously ill patients and their caregivers. Our currentclinical development program includes a second, confirmatory pivotal Phase 3trial of Dimebon(TM) in Alzheimer's disease, a Phase 2 clinical trial ofDimebon in patients with mild-to-moderate Huntington's disease, and a Phase1-2 clinical trial of MDV3100 in patients with castration-resistant (alsoknown as hormone-refractory) prostate cancer. For more information, pleasevisit us at http://www.medivation.com.-- Rodman & Renshaw 5th Annual Global Healthcare Conference on Tuesday, May 20 at 2:40 p.m. local time at Le Meridien Beach Plaza Hotel in Monte Carlo -- UBS Global Specialty and Generic Pharmaceuticals Conference on Wednesday, May 28 at 11:30 a.m. local time at The Waldorf Hilton in Aldwych, London
SOURCE Medivation, Inc.